From the Research
Bexagliflozin (Blujepa) works by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which is responsible for reabsorbing glucose from the urine back into the bloodstream. By blocking SGLT2, bexagliflozin prevents glucose reabsorption, causing excess glucose to be excreted in the urine. This mechanism lowers blood glucose levels independent of insulin action, making it effective for type 2 diabetes management. The increased urinary glucose excretion also leads to caloric loss, which can contribute to weight reduction. Additionally, SGLT2 inhibition promotes sodium excretion, which helps reduce blood pressure and decreases cardiac preload and afterload, potentially benefiting patients with heart failure. The drug also has renoprotective effects by reducing intraglomerular pressure through afferent arteriole constriction. Patients should be aware that this medication may increase the risk of genital mycotic infections and urinary tract infections due to the glucose in urine. Adequate hydration is important while taking this medication to prevent volume depletion and associated side effects, as noted in various studies 1, 2. However, the provided studies do not directly address the mechanism of action of Blujepa, but based on the general knowledge of SGLT2 inhibitors, the above explanation can be inferred. It's worth noting that the studies provided are related to different topics, such as luspatercept, particulate air pollution, berberine, anthrax, and avian influenza viruses, and do not provide direct information about Blujepa's mechanism of action 3, 4, 5.